Senti Biosciences Inc SNTI Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.16 down $0.00, 2.74% at close Nov 6
Last close · Previous close $0.16
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.72Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.16down $0.16, 50.46%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.16Nov 5
- Volume176.49KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume9.45MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.15 to $2.88; now $0.16
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
SNTI trailed the S&P 500 in all 6 periods.
| Period | SNTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SNTI: down 50.5% S&P 500: down 5.6% | SNTI trailed the S&P 500 by 44.9 percentage points Trailed |
| 3M | SNTI: down 55.4% S&P 500: down 4.1% | SNTI trailed the S&P 500 by 51.3 percentage points Trailed |
| YTD | SNTI: down 84.6% S&P 500: up 8.7% | SNTI trailed the S&P 500 by 93.3 percentage points Trailed |
| 1Y | SNTI: down 91.2% S&P 500: up 10.9% | SNTI trailed the S&P 500 by 102.1 percentage points Trailed |
| Long term | ||
| 3Y | SNTI: down 94.5% S&P 500: up 75.0% −62.0% vs +20.5% a year | SNTI trailed the S&P 500 by 169.5 percentage points Trailed |
| 5Y | SNTI: down 99.8% S&P 500: up 67.8% −72.4% vs +10.9% a year | SNTI trailed the S&P 500 by 167.6 percentage points Trailed |
$10,000 invested in SNTI 5 years ago (Nov 5, 2021) would be worth about $16 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
SNTI trailed the S&P 500 in all 6 periods.
| Period | SNTI and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | SNTI: down 50.5% S&P 500: down 5.6% | SNTI trailed the S&P 500 by 44.9 percentage points Trailed |
| 3M | SNTI: down 55.4% S&P 500: down 4.3% | SNTI trailed the S&P 500 by 51.1 percentage points Trailed |
| YTD | SNTI: down 84.6% S&P 500: up 7.8% | SNTI trailed the S&P 500 by 92.4 percentage points Trailed |
| 1Y | SNTI: down 91.2% S&P 500: up 9.7% | SNTI trailed the S&P 500 by 100.9 percentage points Trailed |
| Long term | ||
| 3Y | SNTI: down 94.5% S&P 500: up 68.8% −62.0% vs +19.1% a year | SNTI trailed the S&P 500 by 163.3 percentage points Trailed |
| 5Y | SNTI: down 99.8% S&P 500: up 56.9% −72.4% vs +9.4% a year | SNTI trailed the S&P 500 by 156.7 percentage points Trailed |
$10,000 invested in SNTI 5 years ago (Nov 5, 2021) would be worth about $16 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$102.40
Closing high on . Now 99.8% below that record.
Split-adjusted daily closes since May 26, 2021.
Stock splits
1
1-for-10 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $55.00K
- Net income
- −$49.56M
- Diluted EPS
- −$1.72
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$28.87M | −$6.31 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$610.00K | −$0.62 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$14.11M | −$1.41 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$14.73M | −$0.56 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$18.13M | −$0.69 |
| Q4 FY25 (Dec 31, 2025) | $22.00K | −$14.47M | −$0.48 |
| Q1 FY26 (Mar 31, 2026) | $16.00K | −$4.22M | −$0.14 |
| Q2 FY26 (Jun 30, 2026) | $17.00K | −$12.75M | −$0.41 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $2.76M | −$55.32M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $4.29M | −$58.21M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $2.56M | −$71.06M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $0.00 | −$52.79M | −$12.03 |
| FY25 (Dec 31, 2025) | $22.00K | −$61.44M | −$2.73 |
Margins
- Gross 100.0%
- Operating −111,947.3%
- Net −90,116.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$37.94MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$38.05MLast 12 months
- Capital spending$114.00KLast 12 months
- −68,976.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $10.65MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $7.89MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$20.23MAs of Jun 30, 2026
- Net debt$12.34MAs of Jun 30, 2026
- 0.83As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −1,540.0%Last 12 months
Over the last 12 months, Senti Biosciences lost money: its net loss was 1,540.0% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −113.1%Last 12 months
Over the last 12 months, Senti Biosciences’s net loss was 113.1% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Senti Biosciences Inc
Dynamics Special Purpose Corp Class A
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
SNTI news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
SNTI stock FAQ
What is SNTI stock’s price today?
Senti Biosciences (SNTI) traded at $0.16 at the close on , unchanged from the previous close of $0.16. Over the past 52 weeks it has traded between $0.15 and $2.88.
If you invested $1,000 in SNTI 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in SNTI on would be worth about $2 at the close on , a total return of −99.8%. The same $1,000 would be worth $88 if invested one year ago. Past performance doesn’t predict future returns.
What is SNTI’s P/E ratio?
SNTI’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.72).
How much revenue does Senti Biosciences make?
Senti Biosciences reported $55.0 thousand of revenue over the four quarters to . In its latest quarter (Q2 FY26, ended ) revenue was $17.0 thousand.
Is Senti Biosciences profitable?
Not over the four quarters to . Senti Biosciences reported a net loss of $49.6 million across those four quarters on $55.0 thousand of revenue.
What are SNTI’s earnings per share?
SNTI’s diluted earnings per share were −$1.72 over the four quarters to , compared with −$8.90 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.41 per share, against −$0.56 a year earlier (how EPS works).
Does SNTI pay a dividend?
Senti Biosciences hasn’t paid a dividend in the last twelve months.
What is SNTI’s 52-week high and low?
Over the past 52 weeks SNTI has traded as low as $0.15 and as high as $2.88. At $0.16 at the close on , it is 94.4% below that high and 5.6% above the low.
What is SNTI’s all-time high?
SNTI’s highest closing price was $102.40 on , adjusted for stock splits. At $0.16 at the close on , it is 99.8% below that record.
Has SNTI stock ever split?
Yes, once: 1-for-10 on .
How has SNTI stock performed?
Including dividends and measured to the close on , SNTI has returned −84.6% so far this year and −91.2% over the past year, and −99.8% over five years (−72.4% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Senti Biosciences in?
Senti Biosciences is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does SNTI trade on?
Senti Biosciences trades on the Nasdaq under the ticker symbol SNTI. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.